

Bruce A Chabner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5413786/publications.pdf>

Version: 2024-02-01

102
papers

3,905
citations

293460

24
h-index

139680

61
g-index

105
all docs

105
docs citations

105
times ranked

8241
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC). Cancer Research, 2022, 82, P2-07-02-P2-07-02.	0.4	1
2	Joseph R. Bertino, Scientist and Clinical Oncologist. Journal of Clinical Oncology, 2022, , JCO2102693.	0.8	0
3	Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition. Nature Medicine, 2022, 28, 620-626.	15.2	13
4	Financial Toxicity, Symptom Burden, Illness Perceptions, and Communication Confidence in Cancer Clinical Trial Participants. JCO Oncology Practice, 2022, 18, e1427-e1437.	1.4	4
5	A Medical Pearl Harbor: Pandemic Uncovers Societal Fissures and Leadership Breaches. Oncologist, 2021, 26, 89-89.	1.9	0
6	An Homage to Two Explorers of Uncharted Cancer Waters. Oncologist, 2021, 26, 350-351.	1.9	0
7	Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. Breast Cancer Research and Treatment, 2021, 189, 641-651.	1.1	16
8	The Occasional Reader. Oncologist, 2021, 26, e1484-e1485.	1.9	0
9	Accuracy of Pathologic Diagnosis in Patients With Lymphoma and Survival: A Prospective Analysis From Botswana. JCO Global Oncology, 2021, 7, 1620-1632.	0.8	0
10	Remembering Joe. Oncologist, 2021, 26, 1085-1086.	1.9	0
11	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precision Oncology, 2020, 4, 1246-1262.	1.5	16
12	The Corruption of Science. Oncologist, 2020, 25, 907-908.	1.9	3
13	The Program for Enhanced Training in Cancer: An Initial Experience of Supporting Capacity Building for Oncology Training in Sub-Saharan Africa. JCO Global Oncology, 2020, 6, 13-13.	0.8	1
14	Racism and Cancer Care: A Call for Recognition and Reform. Oncologist, 2020, 25, 729-729.	1.9	3
15	A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases. Oncologist, 2020, 25, 652-660.	1.9	11
16	Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial. Oncologist, 2020, 25, 747-e1273.	1.9	9
17	The Finding of N-Nitrosodimethylamine in Common Medicines. Oncologist, 2020, 25, 460-462.	1.9	15
18	Taking the Longer View of COVID â€19. Oncologist, 2020, 25, 455-457.	1.9	7

#	ARTICLE	IF	CITATIONS
19	Twenty-Five Years of The Oncologist. <i>Oncologist</i> , 2020, 25, 1-2.	1.9	21
20	Cell-free DNA Analysis in Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 501-502.	13.9	12
21	Immuno-Oncology in China. <i>Oncologist</i> , 2019, 24, S1-S2.	1.9	0
22	The Other Opioid Crisis: Just Another Drug Shortage?. <i>Oncologist</i> , 2019, 24, 574-575.	1.9	5
23	POETIC (Program for Enhanced Training in Cancer): An Initial Experience of Supporting Capacity Building for Oncology Training in Sub-Saharan Africa. <i>Oncologist</i> , 2019, 24, 1557-1561.	1.9	12
24	Canakinumab and Lung Cancer: Intriguing, but Is It Real?. <i>Oncologist</i> , 2018, 23, 637-638.	1.9	15
25	Does Chemotherapy Induce Metastases?. <i>Oncologist</i> , 2018, 23, 273-274.	1.9	9
26	Considerations About the Use of Biomarkers in Cancer Clinical Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 25-27.	2.3	2
27	Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana. <i>Journal of Global Oncology</i> , 2018, 4, 1-11.	0.5	14
28	Conflict of Interest: An Ethical Firestorm with Consequences for Cancer Research. <i>Oncologist</i> , 2018, 23, 1391-1393.	1.9	3
29	Application of Cell-free DNA Analysis to Cancer Treatment. <i>New England Journal of Medicine</i> , 2018, 379, 1754-1765.	13.9	634
30	Design and clinical validation of a point-of-care device for the diagnosis of lymphoma via contrast-enhanced microholography and machine learning. <i>Nature Biomedical Engineering</i> , 2018, 2, 666-674.	11.6	55
31	Let This Be Our New Year's Pledge. <i>Oncologist</i> , 2017, 22, 1-2.	1.9	42
32	Regarding "Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies". <i>Oncologist</i> , 2017, 22, 757-758.	1.9	2
33	Advantages of a Truly Open-Access Data-Sharing Model. <i>New England Journal of Medicine</i> , 2017, 376, 1178-1181.	13.9	79
34	The Harm in Kratom. <i>Oncologist</i> , 2017, 22, 1010-1011.	1.9	10
35	On Losing Paddy Johnston. <i>Oncologist</i> , 2017, 22, 1014-1014.	1.9	0
36	Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments. <i>Targeted Oncology</i> , 2017, 12, 719-739.	1.7	71

#	ARTICLE	IF	CITATIONS
37	Thoughts About Greg Curt. <i>Oncologist</i> , 2016, 21, 1277-1277.	1.9	1
38	Holographic Assessment of Lymphoma Tissue (HALT) for Global Oncology Field Applications. <i>Theranostics</i> , 2016, 6, 1603-1610.	4.6	12
39	Reflections on 2015. <i>Oncologist</i> , 2016, 21, 129-130.	1.9	0
40	Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program. <i>Oncologist</i> , 2016, 21, 467-474.	1.9	70
41	While We're at It, Let's Whack the FDA. <i>Oncologist</i> , 2016, 21, 259-260.	1.9	2
42	Understanding the Precision in "Precision Medicine". <i>Oncologist</i> , 2016, 21, 1029-1030.	1.9	0
43	HIV Infection and Survival Among Women With Cervical Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3749-3757.	0.8	129
44	NCI-60 Cell Line Screening: A Radical Departure in its Time. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv388.	3.0	71
45	Recognizing the Financial Burden of Cancer Patients in Clinical Trials. <i>Oncologist</i> , 2015, 20, 572-575.	1.9	43
46	Breakthrough Drugs and Turtle Soup. <i>Oncologist</i> , 2015, 20, 845-846.	1.9	1
47	Structural Approaches to Cancer Drug Development. <i>New England Journal of Medicine</i> , 2015, 373, 402-403.	13.9	2
48	Two Decades of The <i>Oncologist</i> . <i>Oncologist</i> , 2015, 20, 1-2.	1.9	25
49	Ponatinib: Accelerated Disapproval. <i>Oncologist</i> , 2015, 20, 847-848.	1.9	51
50	Improving Prospects for Targeting RAS. <i>Journal of Clinical Oncology</i> , 2015, 33, 3650-3659.	0.8	89
51	Defining a New Role for the National Cancer Institute Cooperative Groups: More Science, Fewer Trials. <i>Oncologist</i> , 2014, 19, 1113-1114.	1.9	1
52	Effective double whammy targets DNA synthesis in leukemia. <i>Journal of Experimental Medicine</i> , 2014, 211, 384-385.	4.2	0
53	The Untimely Passing of a Great Man: Eddie Reed, M.D., 1953-2014. <i>Oncologist</i> , 2014, 19, 786-787.	1.9	1
54	Pharmacodynamic Biomarkers: Falling Short of the Mark?. <i>Clinical Cancer Research</i> , 2014, 20, 2587-2594.	3.2	41

#	ARTICLE	IF	CITATIONS
55	Approval After Phase I: Ceritinib Runs the Three-Minute Mile. <i>Oncologist</i> , 2014, 19, 577-578.	1.9	31
56	Addressing the Growing Cancer Burden in the Wake of the AIDS Epidemic in Botswana: The BOTSOGO Collaborative Partnership. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 468-475.	0.4	34
57	Resolution: Refresh, Recharge, Renew. <i>Oncologist</i> , 2013, 18, 1-1.	1.9	3
58	Approval of New Agents after Phase II Trials. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , e1-e3.	1.8	3
59	Early Accelerated Approval for Highly Targeted Cancer Drugs. <i>New England Journal of Medicine</i> , 2011, 364, 1087-1089.	13.9	74
60	Drug Shortages – A Critical Challenge for the Generic-Drug Market. <i>New England Journal of Medicine</i> , 2011, 365, 2147-2149.	13.9	90
61	About Eli. <i>Oncologist</i> , 2010, 15, 329-331.	1.9	0
62	Obituary. <i>Cancer Science</i> , 2009, 100, 565-566.	1.7	0
63	Advances and challenges in the use of biomarkers in clinical trials. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 42-3.	0.3	2
64	Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.. <i>Blood</i> , 2007, 110, 256-256.	0.6	0
65	Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00.. <i>Blood</i> , 2006, 108, 3454-3454.	0.6	0
66	Chemotherapy and the war on cancer. <i>Nature Reviews Cancer</i> , 2005, 5, 65-72.	12.8	1,646
67	Dose-Adjusted EPOCH-Rituximab Is Highly Effective in the GCB and ABC Subtypes of Untreated Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2004, 104, 159-159.	0.6	4
68	Cancer therapy and survivorship. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 269s.	1.1	0
69	A Staff Dialogue on Caring for an Intensely Spiritual Patient: Psychosocial Issues Faced By Patients, Their Families, and Caregivers. <i>Oncologist</i> , 2002, 7, 16-22.	1.9	2
70	Reality Testing in Cancer Treatment: The Phase I Trial of Endostatin. <i>Oncologist</i> , 2002, 7, 58-65.	1.9	7
71	Cytotoxic Agents in the Era of Molecular Targets and Genomics. <i>Oncologist</i> , 2002, 7, 34-41.	1.9	86
72	A Staff Dialogue on a Socially Distanced Patient: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 2002, 7, 50-57.	1.9	1

#	ARTICLE	IF	CITATIONS
73	A Staff Dialogue on Phase I Trials: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 2002, 7, 8-15.	1.9	4
74	A Staff Dialogue on Caring for a Cancer Patient Who Commits Suicide: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 2002, 7, 30-35.	1.9	22
75	About Sorrow. <i>Oncologist</i> , 2002, 7, 5-6.	1.9	0
76	A Staff Dialogue on Aggressive Palliative Treatment Demanded by a Terminally Ill Patient: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 2002, 7, 23-29.	1.9	4
77	A Staff Dialogue on Do Not Resuscitate Orders: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 2002, 7, 36-42.	1.9	5
78	When Does the Responsibility of Our Care End: Bereavement. <i>Oncologist</i> , 2002, 7, 251-258.	1.9	36
79	Cytotoxic Agents in the Era of Molecular Targets and Genomics. <i>Oncologist</i> , 2002, 7, 34-41.	1.9	5
80	Reality Testing in Cancer Treatment: The Phase I Trial of Endostatin. <i>Oncologist</i> , 2002, 7, 58-65.	1.9	0
81	A Staff Dialogue on a Socially Distanced Patient: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 2002, 7, 50-57.	1.9	0
82	A Staff Dialogue on Phase I Trials: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 2002, 7, 8-15.	1.9	0
83	A Staff Dialogue on Aggressive Palliative Treatment Demanded by a Terminally Ill Patient: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 2002, 7, 23-29.	1.9	0
84	About Sorrow. <i>Oncologist</i> , 2002, 7, 5-6.	1.9	0
85	A Staff Dialogue on Caring for a Cancer Patient Who Commits Suicide: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 2002, 7, 30-35.	1.9	4
86	Losing God. <i>Oncologist</i> , 2001, 6, 286-297.	1.9	12
87	Complementary, Alternative, Integrative, or Unconventional Medicine?. <i>Oncologist</i> , 2001, 6, 463-473.	1.9	24
88	Medical Mistakes: A Workshop on Personal Perspectives. <i>Oncologist</i> , 2001, 6, 92-99.	1.9	45
89	Caring for Colleagues. <i>Oncologist</i> , 2001, 6, 197-204.	1.9	4
90	New Drugs for Cancer: Temozolomide. <i>Oncologist</i> , 2000, 5, 0-1.	1.9	0

#	ARTICLE	IF	CITATIONS
91	Communicating Genetic Risk: Pros, Cons, and Counsel. <i>Oncologist</i> , 2000, 5, 152-161.	1.9	5
92	Sexuality and Cancer: Conversation Comfort Zone. <i>Oncologist</i> , 2000, 5, 336-344.	1.9	52
93	A Staff Dialogue on Caring for a Cancer Patient Who Commits Suicide: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 1999, 4, 122-127.	1.9	1
94	A Staff Dialogue on Aggressive Palliative Treatment Demanded by a Terminally Ill Patient: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 1999, 4, 70-76.	1.9	3
95	A Staff Dialogue on Do Not Resuscitate Orders: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 1999, 4, 256-262.	1.9	7
96	A Staff Dialogue on a Socially Distanced Patient: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 1999, 4, 417-424.	1.9	1
97	Reality Testing in Cancer Treatment: The Phase I Trial of Endostatin. <i>Oncologist</i> , 1999, 4, 501-508.	1.9	17
98	Clinical evaluation of biologically targeted drugs: Obstacles and opportunities. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, S3-S21.	1.1	25
99	A Staff Dialogue on Caring for an Intensely Spiritual Patient: Psychosocial Issues Faced By Patients, Their Families, and Caregivers. <i>Oncologist</i> , 1998, 3, 439-445.	1.9	3
100	A Staff Dialogue on Phase I Trials: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. <i>Oncologist</i> , 1998, 3, 357-364.	1.9	3
101	Back to the Future for Clinical Oncology. <i>Oncologist</i> , 1996, 1, i-i.	1.9	2
102	Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders. <i>Oncologist</i> , 1996, 1, 125-139.	1.9	14